Controlled dual delivery of BMP-2 and dexamethasone by nanoparticle-embedded electrospun nanofibers for the efficient repair of critical-sized rat calvarial defect

Biomaterials

Volumn 37, Issue , 2015, Pages 218-229

  Li, Long ^a   Zhou, Guangliang ^a   Wang, Yi ^a   Yang, Guang ^a   Ding, Shan ^a   Zhou, Shaobing ^a  

^a SOUTHWEST JIAOTONG UNIVERSITY   (China)

Author keywords

Critical bone defect; Drug delivery; Electrospinning; Nanofiber; Nanoparticle; Tissue engineering

Indexed keywords

BIOMIMETICS; BLENDING; BODY FLUIDS; BONE; DEFECTS; DRUG DELIVERY; ELECTROSPINNING; NANOFIBERS; NANOPARTICLES; POLYETHYLENE GLYCOLS; RATS; REPAIR; SCAFFOLDS (BIOLOGY); TARGETED DRUG DELIVERY; TISSUE; TISSUE ENGINEERING;

BIOMIMETIC BONE TISSUES; BONE DEFECT; BONE TISSUE ENGINEERING; BOVINE SERUM ALBUMINS; ELECTROSPUN NANOFIBERS; NANOFIBER SCAFFOLD; POLY (EPSILONCAPROLACTONE); SYNERGISTIC EFFECT;

CONTROLLED DRUG DELIVERY;

BONE MORPHOGENETIC PROTEIN 2; BOVINE SERUM ALBUMIN; COPOLYMER; DEXAMETHASONE; NANOFIBER; NANOPARTICLE; POLY(EPSILON CAPROLACTONE) CO POLY(ETHYLENE GLYCOL); UNCLASSIFIED DRUG; ALKALINE PHOSPHATASE; DELAYED RELEASE FORMULATION; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; BONE DEVELOPMENT; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELECTROSPINNING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; NANOENCAPSULATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SKULL DEFECT; SUSTAINED DRUG RELEASE; ANIMAL; BOVINE; CHEMISTRY; CYTOLOGY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; ENZYMOLOGY; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PROCEDURES; SKULL; SPRAGUE DAWLEY RAT; STAINING; TISSUE ENGINEERING; TISSUE SCAFFOLD; ULTRASTRUCTURE; WOUND HEALING;

BOVINAE; RATTUS;

ALKALINE PHOSPHATASE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CATTLE; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; FEMALE; HUMANS; MESENCHYMAL STROMAL CELLS; NANOFIBERS; NANOPARTICLES; OSTEOGENESIS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SKULL; STAINING AND LABELING; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 84922219802     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.10.015     Document Type: Article

References (64)

1. Hokugo A., Saito T., Li A., Sato K., Tabata Y., Jarrahy R. Stimulation of bone regeneration following the controlled release of water-insoluble oxysterol from biodegradable hydrogel. Biomaterials 2014, 35:5565-5571.
2. Mehta M., Schmidt-Bleek K., Duda G.N., Mooney D.J. Biomaterial delivery of morphogens to mimic the natural healing cascade in bone. Adv Drug Deliv Rev 2012, 64:1257-1276.
3. Amini A., Laurencin C., Nukavarapu S. Bone tissue engineering: recent advances and challenges. Crit Rev Biomed Eng 2012, 40:363-408.
4. Delloye C., Cornu O., Barbier O. Bone allografts: what they can offer and what they cannot. JBone Jt Surg Br 2007, 89:574-579.
5. Li H.Y., Xue K., Kong N., Liu K., Chang J. Silicate bioceramics enhanced vascularization and osteogenesis through stimulating interactions between endothelia cells and bone marrow stromal cells. Biomaterials 2014, 35:3803-3818.
6. Stevens M. Biomaterials for bone tissue engineering. Mater Today 2008, 11:18-25.
7. Burg K.J., Porter S., Kellam J.F. Biomaterial developments for bone tissue engineering. Biomaterials 2000, 21:2347-2359.
8. Hutmacher D.W. Scaffolds in tissue engineering bone and cartilage. Biomaterials 2000, 21:2529-2543.
9. Groeneveld E.H.J., Burger E.H. Bone morphogenetic proteins in human bone regeneration. Eur J Endocrinol 2000, 142:9-21.
10. Cao L.Y., Wang J., Hou J., Xing W.L., Liu C.S. Vascularization and bone regeneration in a critical sized defect using 2-N,6-O-sulfated chitosan nanoparticles incorporating BMP-2. Biomaterials 2014, 35:684-698.
11. Cao L.Y., Werkmeister J.A., Wang J., Glattauer V., Mclean K.M., Liu C.S. Bone regeneration using photocrosslinked hydrogel incorporating rhBMP-2 loaded2-N, 6-O-sulfated chitosan nanoparticles. Biomaterials 2014, 35:2730-2742.
12. Takahashi Y., Yamamoto M., Tabeta Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate. Biomaterials 2005, 26:4856-4865.
13. Kaneko H., Arakawa T., Mano H., Kaneda T., Ogasawara A., Nakagawa M., et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 2000, 27:479-486.
14. Langenfeld E.M., Kong Y., Langenfeld J. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5. Oncogene 2006, 25:685-692.
15. Liu F., Bloch N., Bhushan K.R., De Grand A.M., Tanaka E., Solazzo S., et al. Humoral BMP-2 is sufficient for inducing breast cancer microcalcification. Mol Imaging 2008, 7:175-186.
16. Petite H., Viateau V., Bensaid W., Meunier A., de Pollak C., Bourguignon M., et al. Tissue-engineered bone regeneration. Nat Biotechnol 2000, 18:959-963.
17. Kim H., Kim H.W., Suh H. Sustained release of ascorbate-2-phosphate and dexamethasone from porous PLGA scaffolds for bone tissue engineering using mesenchymal stem cells. Biomaterials 2003, 24:4671-4679.
18. Oshina H., Sotome S., Yoshii T., Torigoe I., Sugata Y., Maehara H., et al. Effects of continuous dexamethasone treatment on differentiation capabilities of bone marrow-derived mesenchymal cells. Bone 2007, 41:575-583.
19. Kaji H., Sugimoto T., Kanatani M., Nishiyama K., Chihara K. Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. JBone Miner Res 1997, 12:734-741.
20. Jaiswal N., Haynesworth S.E., Caplan A.I., Bruder S.P. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells invitro. JCell Biochem 1997, 64:295-312.
21. Martins A., Duarte A.R.C., Faria S., Marques A.P., Reis R.L., Neves N.M. Osteogenic induction of hBMSCs by electrospun scaffolds with dexamethasone release functionality. Biomaterials 2010, 31:5875-5885.
22. Wang X., Ding B., Li B. Biomimetic electrospun nanofibrous structures for tissue engineering. Mater Today 2013, 16:229-241.
23. Hollister S.J. Porous scaffold design for tissue engineering. Nat Mater 2005, 4:518-524.
24. Kanematsu A., Yamamoto S., Ozeki M., Noguchi T., Kanatani I., Ogawa O., et al. Collagenous matrices as release carriers of exogenous growth factors. Biomaterials 2004, 25:4513-4520.
25. Jones J.R., Lee P.D., Hench L.L. Hierarchical porous materials for tissue engineering. Philos Trans A Math Phys Eng Sci 2006, 364:263-281.
26. Su Y., Su Q., Liu W., Lim M., Venugopal J.R., Mo X., et al. Controlled release of bone morphogenetic protein 2 and dexamethasone loaded in core-shell PLLACL-collagen fibers for use in bone tissue engineering. Acta Biomater 2012, 8:763-771.
27. Liu S., Qin M., Hu C., Wu F., Cui W., Jin T., et al. Tendon healing and anti-adhesion properties of electrospun fibrous membranes containing bFGF loaded nanoparticles. Biomaterials 2013, 34:4690-4701.
28. Ji W., Sun Y., Yang F., van den Beucken J.J.P., Fan M., Chen Z., et al. Bioactive electrospun scaffolds delivering growth factors and genes for tissue engineering applications. Pharm Res 2011, 28:1259-1272.
29. Jang J.H., Castano O., Kim H.W. Electrospun materials as potential platforms for bone tissue engineering. Adv Drug Deliv Rev 2009, 61:1065-1083.
30. Logeart-Avramoglou D., Anagnostou F., Bizios R., Petite H. Engineering bone: challenges and obstacles. JCell Mol Med 2005, 9:72-84.
31. Zeltinger J., Sherwood J.K., Graham D.A., Mueller R., Griffith L.G. Effect of pore size and void fraction on cellular adhesion, proliferation, and matrix deposition. Tissue Eng 2001, 7:557-572.
32. Porter J.R., Ruckh T.T., Popat K.C. Bone tissue engineering: a review in bone biomimetics and drug delivery strategies. Biotechnol Prog 2009, 25:1539-1560.
33. Hassan W., Dong Y.X., Wang W.X. Encapsulation and 3D culture of human adipose-derived stem cells in an in-situ crosslinked hybrid hydrogel composed of PEG-based hyperbranched copolymer and hyaluronic acid. Stem Cell Res Ther 2013, 4:368-373.
34. Zhou S.B., Deng X.M., Yang H. Biodegradable poly(ε-caprolactone)-poly(ethylene glycol) block copolymers: characterization and their use as drug carriers for a controlled delivery system. Biomaterials 2003, 24:3563-3570.
35. Marty J., Oppenheim R., Speiser P. Nanoparticles - a new colloidal drug delivery system. Pharm Acta Helv 1978, 53:17-23.
36. Shao S.J., Zhou S.B., Li L., Li J.R., Luo C., Wang J.X., et al. Osteoblast function on electrically conductive electrospun PLA/MWCNTs nanofibers. Biomaterials 2011, 32:2821-2833.
37. Luo C., Li L., Li J.R., Yang G., Ding S., Zhi W., et al. Modulating cellular behaviors through surface nanoroughness. JMater Chem 2012, 22:15654-15664.
38. Wei Z., Wang C., Zou S., Liu H., Tong Z. Chitosan nanoparticles as particular emulsifier for preparation of novel pH-responsive pickering emulsions and PLGA microcapsules. Polymer 2012, 53:1229-1235.
39. Papadimitriou S., Bikiaris D., Avgoustakis K., Karavas E., Georgarakis M. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym 2008, 73:44-54.
40. Grenha A., Seijo B., Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005, 25:427-437.
41. Srouji S., Ben-David D., Lotan R., Livne E., Avrahami R., Zussman E. Slow-release human recombinant bone morphogenetic protein-2 embedded within electrospun scaffolds for regeneration of bone defect: invitro and invivo evaluation. Tissue Eng Part A 2011, 17:269-277.
42. Hofmann D., Entrialgo-Castaño M., Kratz K., Lendlein A. Knowledge-Based approach towards hydrolytic degradation of polymer-based biomaterials. Adv Mater 2009, 21:3237-3245.
43. Zhang Q.C., Jiang Y., Zhang Y., Ye Z.Y., Tan W.S., Lang M.D. Effect of porosity on long-term degradation of poly (ε-caprolactone) scaffolds and their cellular response. Polym Degrad Stab 2013, 98:209-218.
44. Pound J.C., Green D.W., Roach H.I., Mann S., Oreffo R.O.C. An exvivo model for chondrogenesis and osteogenesis. Biomaterials 2007, 28:2839-2849.
45. Elzoghby A.O., Samy W.M., Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. JControl Release 2012, 157:168-182.
46. Zhang S., Doschak M.R., Uludağ H. Pharmacokinetics and bone formation by BMP-2 entrapped in polyethylenimine-coated albumin nanoparticles. Biomaterials 2009, 30:5143-5155.
47. Chen W., Gu B., Wang H., Pan J., Lu W., Hou H. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm 2008, 362:133-140.
48. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8:1038-1044.
49. Geny B., Mettauer B., Muan B., Bischoff P., Epailly E., Piquard F., et al. Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients. JAm Coll Cardiol 1993, 22:1193-1198.
50. Zhang S., Wang G., Lin X., Chatzinikolaidou M., Jennissen H.P., Laub M., et al. Polyethylenimine-coated albumin nanoparticles for BMP-2 delivery. Biotechnol Prog 2008, 24:945-956.
51. Wang G., Siggers K., Zhang S., Jiang H., Xu Z., Zernicke R.F., et al. Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res 2008, 25:2896-2909.
52. Yoon J.J., Kim J.H., Park T.G. Dexamethasone-releasing biodegradable polymer scaffolds fabricated by a gas-foaming/salt-leaching method. Biomaterials 2003, 24:2323-2329.
53. Rawadi G., Vayssière B., Dunn F., Baron R., Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. JBone Miner Res 2003, 18:1842-1853.
54. Jäger M., Fischer J., Dohrn W., Li X., Ayers D.C., Czibere A., et al. Dexamethasone modulates BMP-2 effects on mesenchymal stem cells invitro. JOrthop Res 2008, 26:1440-1448.
55. Li J., Fu R., Li L., Yang G., Ding S., Zhong Z., et al. Co-delivery of dexamethasone and green tea polyphenols using electrospun ultrafine fibers for effective treatment of keloid. Pharm Res 2014, 31:1632-1643.
56. Ding S., Li J.R., Luo C., Li L., Yang G., Zhou S.B. Synergistic effect of released dexamethasone and surface nanoroughness on mesenchymal stem cell differentiation. Biomater Sci 2013, 1:1091-1100.
57. Zhu L., Skoultchi A.I. Coordinating cell proliferation and differentiation. Curr Opin Genet Dev 2001, 11:91-97.
58. Luvizuto E.R., Tangl S., Zanoni G., Okamoto T., Sonoda C.K., Gruber R., et al. The effect of BMP-2 on the osteoconductive properties of beta-tricalcium phosphate in rat calvaria defects. Biomaterials 2011, 32:3855-3861.
59. Ben-David D., Srouji S., Shapira-Schweitzer K., Kossover O., Ivanir E., Kuhn G., et al. Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen hydrogel matrix. Biomaterials 2013, 34:2902-2910.
60. Kempen D.H., Lu L., Heijink A., Hefferan T.E., Creemers L.B., Maran A., et al. Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials 2009, 30:2816-2825.
61. Matsuo K., Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008, 473:201-209.
62. Chen G.Q., Deng C.X., Li Y.P. TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012, 8:272-288.
63. Hamidouche Z., Fromigué O., Nuber U., Vaudin P., Pages J.C., Ebert R., et al. Autocrine fibroblast growth factor 8 mediates dexamethasone-induced osteogenic differentiation of murine mesenchymal stem cells. JCell Physiol 2010, 224:509-515.
64. Heldin C.H., Miyazono K., Dijke P.T. TGF-bold beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.